aprotinin

A January 26, 2006, article published in the New England Journal of Medicine (NEJM) described the findings from an observational study of 4,374 patients (1,295 treated with Trasylol) scheduled for CABG surgery at multiple centers in multiple countries. 

Compared to those receiving no preventive drug therapy and after propensity adjustment, primary patientsreceiving Trasylol had a higher risk for dialysis or creatinine increase; myocardial infarction or heart failure; or stroke, encephalopathy or coma.  Compared to those receiving no preventive drug therapy and after propensity adjustment, complex patients receiving Trasylol had a higher risk for dialysis or creatinine increase, but not for heart complications, stroke, encephalopathy or coma.  Risks for adverse renal events increased with the administered Trasylol dose.  All three drug therapies (Trasylol, aminocaproic acid or tranexamic acid) were reported to reduce blood loss to similar extents.

risk for death, kidney failure, congestive heart failure and stroke. 

in secondary exposures- risk of anaphylaxis